Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q15818
UPID:
NPTX1_HUMAN
Alternative names:
Neuronal pentraxin I
Alternative UPACC:
Q15818; B3KXH3; Q5FWE6
Background:
Neuronal pentraxin-1, alternatively known as Neuronal pentraxin I, plays a crucial role in synaptic remodeling and the synaptic clustering of AMPA glutamate receptors at certain excitatory synapses. Its involvement in these processes is essential for the proper functioning of neuronal circuits.
Therapeutic significance:
Spinocerebellar ataxia 50, a disorder characterized by progressive incoordination and cerebellar atrophy, is linked to variants affecting Neuronal pentraxin-1. Understanding the role of Neuronal pentraxin-1 could open doors to potential therapeutic strategies for this debilitating condition.